Aromatase and its inhibitors--an overview

Area of Science:

• Endocrinology and oncology
• Pharmacology of hormone therapies

Background:

• Estrogen synthesis via aromatase is crucial for hormone-dependent breast cancer growth.
• Aromatase inhibitors offer a therapeutic strategy to reduce estrogen levels.
• Both steroidal and non-steroidal inhibitors have been developed.

Purpose of the Study:

• To evaluate the efficacy and safety of 4-hydroxyandrostenedione (4-OHA) as an aromatase inhibitor in treating breast cancer.
• To assess the impact of 4-OHA on estrogen levels, tumor response, and gonadotropin levels in preclinical models and human patients.

Main Methods:

• In vivo studies in rats and non-human primates to assess aromatase inhibition and estrogen reduction.
• Dose-ranging studies in postmenopausal breast cancer patients treated with 4-OHA.
• Evaluation of plasma estrogen concentrations, gonadotropin levels, and tumor response (regression or stabilization).

Main Results:

• 4-OHA effectively inhibited aromatase activity and reduced plasma estrogen levels in animal models, correlating with mammary tumor regression.
• In postmenopausal patients, 4-OHA significantly reduced plasma estrogen concentrations without affecting gonadotropin levels.
• Complete or partial tumor regression was observed in 26% of patients, with disease stabilization in 25%.

Conclusions:

• 4-hydroxyandrostenedione (4-OHA) demonstrates significant estrogen-lowering effects and clinical benefit in postmenopausal breast cancer patients with relapsed disease.
• Aromatase inhibitors, including steroidal compounds like 4-OHA, represent a valuable addition to breast cancer treatment strategies.
• Further development of potent and selective aromatase inhibitors is ongoing for improved breast cancer therapy.